Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The new module introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform automates complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.
The launch of ZetaOmics is significant as it represents a shift from Lantern’s primary focus on internal drug development to offering a commercial platform that can serve the broader biomedical research community. By providing an autonomous computational biologist, the platform aims to reduce the time and expertise required for complex bioinformatics analyses, potentially accelerating discovery in oncology and other fields. The ability to detect flaws in experimental design and provide a complete audit trail addresses common issues in research reproducibility, a growing concern across scientific disciplines.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information, visit the full press release at https://ibn.fm/9sIIl.
